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INFLAMMATION AND INFLAMMATORY BOWEL DISEASE
Effect of Pentavac and measles-mumps-rubella (MMR)
vaccination on the intestine
B Thjodleifsson, K Davídsdóttir, U Agnarsson, G Sigthórsson, M Kjeld, I Bjarnason
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Background: The safety of infant vaccination has been questioned in recent years. In particular it has
been suggested that the measles, mumps, and rubella (MMR) vaccination leads to brain damage mani-
festing as autism consequent to the development of an “enterocolitis” in the immediate post-vaccination
period.
Aim: To assess if MMR vaccination is associated with subclinical intestinal inflammation, which is cen-
tral to the autistic “enterocolitis” theory.
Methods: We studied 109/58 infants, before and two and four weeks after immunisation with Penta-
vac and MMR vaccines, for the presence of intestinal inflammation (faecal calprotectin).
Results: Neither vaccination was associated with any significant increase in faecal calprotectin con-
centrations.
Conclusions: The failure of the MMR vaccination to cause an intestinal inflammatory response
provides evidence against the proposed gut-brain interaction that is central to the autistic “enterocoli-
tis” hypothesis.
The presence of lymphoid nodular hyperplasia and colitisin autistic children, termed autistic “enterocolitis”, withvarious gastrointestinal symptoms investigated a number
of years after immunisation is not in doubt.1 2 However, the
aetiology and pathogenesis of the intestinal inflammation is
controversial3 as is the possible role of the intestine in the
development of the central nervous system dysfunction that
may manifest in mental health disorders.4 5
One hypothesis of the pathophysiology of autistic “entero-
colitis” postulates that the measles vaccination virus of the
measles, mumps, and rubella (MMR) vaccine escapes initial
detection by the immune system3 and disseminates to the
intestinal lymphoid tissue. Here, it is suggested, it leads to an
“enterocolitis” with increased permeation of neurotoxic lumi-
nal substances during a vulnerable part of brain development,
leading to regressive autism.3 6 Central to this hypothesis is the
development of intestinal inflammation in the immediate
period following vaccination.
We tested this hypothesis by assessing intestinal inflamma-
tion (faecal calprotectin) before and after Pentavac and MMR
vaccination in a group of infants.
SUBJECTS AND METHODS
Iceland has a developed health service with a centralised vac-
cination programme that results in infant vaccination rates
approaching 100%. Pentavac (Pasteur Mérieux, France) vacci-
nation (against diphtheria, tetanus, pertussis, polio, Haemo-
philus influenza type b) is performed at three, five, and 12
months of age and MMR (Priorix; SmithKline Beecham) vac-
cination at 18 months. One hundred and nine infants attend-
ing two of the vaccination centres of Southwest Iceland
participated. These were consecutive infants where the
parents had been sent a pre-attendance information leaflet
explaining the nature and aims of the research. All of those
approached participated. No infant met the predetermined
specific exclusion criteria to this study which included those
specified by the makers of the vaccines, the presence of intes-
tinal diseases, or ingestion of medications that are associated
with intestinal permeability-inflammation.7
The infants were studied by measuring faecal calprotectin
(Calprest, Calprotech Ltd, London, UK) one week before Pen-
tavac (at 12 months of age) and MMR (at 18 months) vacci-
nation, and two and four weeks later, respectively. Pentavac
does not contain mercury, which has been proposed to predis-
pose to the toxicity of MMR.8 The pre-Pentavac measurement
served as the normal reference range. The faecal calprotectin
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Abbreviations: MMR, measles-mumps-rubella.
Table 1 Faecal calprotectin concentrations (mg/l) before and after Pentavac and
measles-mumps-rubella (MMR) vaccination
Pentavac MMR
Pre Post Pre Post
0 week 2 weeks 4 weeks 0 week 2 weeks 4 weeks
n 109 101 89 81 63 58
Median 39 40 37 36 38 46
Range 3–218 1–295 1–273 1–292 3–207 5–299
There were no significant differences between calprotectin levels at the different time points and sequential
studies showed no significant changes following vaccination.
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assay differs somewhat from many of the published ones,9–12
mainly in the extraction procedure and amount of stool
required for assay (200 mg rather than 5 g). The Calprest
method gives calprotectin values that are approximately five
times higher than the older method,13 with improved
sensitivity14 for the detection of intestinal inflammation in
adults.
All parents provided written informed consent and the
studies were approved by the National University Hospital
Ethics Committee.
RESULTS
Table 1 shows the median (range) values for faecal calprotec-
tin concentrations in infants. There were no statistically
significant differences in faecal calprotectin concentrations at
any time points (p>0.25) (Friedman’s two way analyses of
variance) or when assessed in subjects studied before and
after Pentavac (p>0.2) or MMR (p>0.3) vaccination (paired
Student’s t test on logarithmically transformed data which
were normally distributed).
DISCUSSION
Naturally occurring measles viral infection has a predilection
for the intestinal lymphoid tissue and may cause intestinal
inflammation, which on occasions may resemble Crohn’s
disease.15 16 The measles virus has controversially17 been impli-
cated in the pathogenesis of Crohn’s disease18–20 and other dis-
eases, including multiple sclerosis.21 The suggestion that the
live attenuated measles vaccine might lead to ileocolonic
inflammation with autistic features1 2 has caused equal inter-
est. This hypothesis was formulated in an attempt to explain
the high prevalence of “enterocolitis” in autistic children with
gastrointestinal symptoms.1 6 Consequent to the measles vac-
cine virus induced ileocolonic inflammation, it is suggested,
there is increased intestinal permeation of a variety of intesti-
nally derived neuroactive peptides that interfere with brain
development.6 22–24 In support of this hypothesis are reports of
intestinal pathology1 2 and abnormal intestinal function in
children with autism25–27 when examined a number of years
after the vaccination. These data are not particularly
controversial but rather highlight the possible role and effect
of the measles vaccination virus in the development of this
inflammation in the immediate post-vaccination period and
the postulated consequential effect on brain function.
In this study we specifically assessed the possibility that
MMR vaccination leads to subclinical intestinal inflammation
in infants undergoing immunisation. The upper limit of faecal
concentrations of calprotectin (110 mg/l; 95% confidence lim-
its (2 SD) calculated from logarithmically transformed mean
data) before vaccinations at 12 and 18 months of age are com-
parable with published data in normal infants of the same
age28–30 and are twice as high as those reported in healthy
adults. Pathological intestinal inflammation is easily differen-
tiated from normal as faecal calprotectin values are usually
well in excess of 1000 mg/l28 29 under these circumstances.
There was no evidence that either Pentavac or MMR vacci-
nation provoked subclinical intestinal inflammation in any of
our apparently healthy children during the four week
post-vaccination period. This lack of a detectable intestinal
inflammatory response suggests that the measles vaccine
virus itself is not enterotoxic in healthy infants which argues
against the MMR induced autistic “enterocolitis” theory. This
does not however rule out the possibility that vaccination
might have an adverse effect on susceptible infants that are
perhaps immune compromised or with an immunological
makeup that predisposes them to autoimmune disease.31
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